收费全文 | 47504篇 |
免费 | 3972篇 |
国内免费 | 111篇 |
耳鼻咽喉 | 381篇 |
儿科学 | 1992篇 |
妇产科学 | 1303篇 |
基础医学 | 6821篇 |
口腔科学 | 978篇 |
临床医学 | 6564篇 |
内科学 | 9250篇 |
皮肤病学 | 899篇 |
神经病学 | 4823篇 |
特种医学 | 1084篇 |
外科学 | 4287篇 |
综合类 | 408篇 |
一般理论 | 62篇 |
预防医学 | 5747篇 |
眼科学 | 675篇 |
药学 | 2663篇 |
2篇 | |
中国医学 | 54篇 |
肿瘤学 | 3594篇 |
2024年 | 41篇 |
2023年 | 398篇 |
2022年 | 401篇 |
2021年 | 1277篇 |
2020年 | 948篇 |
2019年 | 1400篇 |
2018年 | 1535篇 |
2017年 | 1211篇 |
2016年 | 1346篇 |
2015年 | 1411篇 |
2014年 | 1797篇 |
2013年 | 2653篇 |
2012年 | 3684篇 |
2011年 | 3809篇 |
2010年 | 2095篇 |
2009年 | 1854篇 |
2008年 | 3084篇 |
2007年 | 3170篇 |
2006年 | 3138篇 |
2005年 | 2941篇 |
2004年 | 2856篇 |
2003年 | 2602篇 |
2002年 | 2344篇 |
2001年 | 392篇 |
2000年 | 293篇 |
1999年 | 335篇 |
1998年 | 536篇 |
1997年 | 398篇 |
1996年 | 360篇 |
1995年 | 349篇 |
1994年 | 276篇 |
1993年 | 278篇 |
1992年 | 202篇 |
1991年 | 172篇 |
1990年 | 163篇 |
1989年 | 123篇 |
1988年 | 142篇 |
1987年 | 109篇 |
1986年 | 112篇 |
1985年 | 114篇 |
1984年 | 108篇 |
1983年 | 113篇 |
1982年 | 132篇 |
1981年 | 129篇 |
1980年 | 105篇 |
1979年 | 62篇 |
1978年 | 71篇 |
1977年 | 59篇 |
1976年 | 48篇 |
1972年 | 37篇 |
Introduction
Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes. This trial compared the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian subjects.Methods
In this single-center, double-blind, parallel-group, 13-week trial, 44 healthy male subjects (22 Japanese, 22 Caucasian) were randomized within each race to semaglutide 0.5 mg (n = 8), 1.0 mg (n = 8), placebo 0.5 mg (n = 3) or 1.0 mg (n = 3). The primary endpoint was semaglutide exposure at steady state [area under the curve (AUC0–168h)].Results
Steady-state exposure of semaglutide was similar for both populations: AUC0–168h estimated race ratio (ERR), Japanese/Caucasian: 0.5 mg, 1.06; 1.0 mg, 0.99; maximum concentration (Cmax) ERR: 0.5 mg, 1.06; 1.0 mg, 1.02. Exposure after the first dose (0.25 mg) was slightly higher in Japanese versus Caucasian subjects (AUC0–168h ERR 1.11; Cmax ERR 1.14). Dose-dependent increases in AUC0–168h and Cmax occurred in both populations. Accumulation was as expected, based on the half-life (t1/2, ~ 1 week) and dosing interval of semaglutide. Significant body weight reductions were observed with semaglutide 0.5 mg and 1.0 mg in Japanese (both p ≤ 0.05) and Caucasian (both p ≤ 0.05) subjects versus placebo. No new safety issues were identified.Conclusions
The pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide were similar in Japanese and Caucasian subjects, suggesting that no dose adjustment is required for the clinical use of semaglutide in Japanese subjects.Funding
Novo Nordisk A/S, Denmark.Trial registration
ClinicalTrials.gov identifier NCT02146079. Japanese trial registration number JapicCTI-142550.Context
Pain is a common and distressing symptom. Pain management is a core competency for palliative care (PC) teams.Objective
Identify characteristics associated with pain and pain improvement among inpatients referred to PC.Methods
Thirty-eight inpatient PC teams in the Palliative Care Quality Network entered data about patients seen between December 12, 2012 and March 15, 2016. We examined patient and care characteristics associated with pain and pain improvement.Results
Of patients who could self-report symptoms, 30.7% (4959 of 16,158) reported moderate-to-severe pain at first assessment. Over 40% of these patients had not been referred to PC for pain. Younger patients (P < 0.0001), women (P < 0.0001), patients with cancer (P < 0.0001), and patients in medical/surgical units (P < 0.0001) were more likely to report pain. Patients with pain had higher rates of anxiety (P < 0.0001), nausea (P < 0.0001), and dyspnea (P < 0.0001). Sixty-eight percent of patients with moderate-to-severe pain improved by the PC team's second assessment within 72 hours; 74.7% improved by final assessment. There was a significant variation in the rate of pain improvement between PC teams (P < 0.0001). Improvement in pain was associated with improvement in anxiety (OR = 2.9, P < 0.0001) and dyspnea (OR = 1.4, P = 0.03). Patients who reported an improvement in pain had shorter hospital length-of-stay by two days (P = 0.003).Conclusion
Pain is common among inpatients referred to PC. Three-quarters of patients with pain improve and improvement in pain is associated with other symptom improvement. Standardized, multisite data collection can identify PC patients likely to have marked and refractory pain, create benchmarks for the field, and identify best practices to inform quality improvement. 相似文献Materials and methods: We conducted a scoping study including research published between January 2013 and December 2016, evaluating effectiveness of rehabilitation following hip and knee total joint replacement. We reviewed this work in the context of outcomes described from previously published research.
Results: Thirty individual studies and seven systematic reviews were included, with most research examining the effectiveness of physiotherapy-based exercise rehabilitation after total knee replacement using randomized control trial methods. Rehabilitation after hip and knee replacement whether carried out at the clinic or monitored at home, appears beneficial but type, intensity and duration of interventions were not consistently associated with outcomes. The burden of comorbidities rather than specific rehabilitation approach may better predict rehabilitation outcome. Monitoring of recovery and therapeutic attention appear important but little is known about optimal levels and methods required to maximize outcomes.
Conclusions: More work exploring the role of comorbidities and key components of therapeutic attention and the therapy relationship, using a wider range of study methods may help to advance the field.
- Implications for Rehabilitation
Physiotherapy-based exercise rehabilitation after total hip replacement and total knee replacement, whether carried out at the clinic or monitored at home, appears beneficial.
Type, intensity, and duration of interventions do not appear consistently associated with outcomes.
Monitoring a patient’s recovery appears to be an important component. The available research provides limited guidance regarding optimal levels of monitoring needed to achieve gains following hip and knee replacement and more work is required to clarify these aspects.
The burden of comorbidities appears to better predict outcomes regardless of rehabilitation approach.
Design: Retrospective case series.
Material and Methods: In this retrospective case series, we present 2 patients (3 eyes) with Type C dural CCFs, who had failed cannulation via the conventional transfemoral route and the transorbital superior ophthalmic vein approach. They subsequently underwent CCF occlusion via an anterior orbital approach through the medial ophthalmic veins, at the Department of Ophthalmology, National University Hospital Singapore. CCF occlusion was confirmed intraoperatively using angiography. Both patients were evaluated postoperatively for best-corrected visual acuity and resolution of clinical signs and symptoms.
Results: Successful occlusion of CCFs via the medial ophthalmic veins were achieved in all three orbits, with excellent visual and cosmetic outcomes postoperatively.
Conclusion: Dural CCFs may potentially lead to severe visual dysfunction and should be diagnosed and treated promptly. When all venous routes have been exhausted, the transorbital approach via the medial ophthalmic vein remains an excellent and viable alternative to access the fistula. Close cooperation between the orbital, anesthetic and radiological teams is essential in ensuring success of the operation. 相似文献